Table-I.

Subgroup analysis of outcomes.

Subgroups	Risk of in-hospital mortality	Risk of mortality at 3 months	Risk of mortality at 1 year of more	Risk of poor functional outcome
	Pooled odds ratio (OR) with 95% CI (Number of studies; I2)	Pooled odds ratio (OR) with 95% CI (Number of studies; I2)	Pooled Hazard ratio (HR) with 95% CI (Number of studies; I2)	Pooled odds ratio (OR) with 95% CI (Number of studies; I2)
Study design
Prospective cohort	1.47 (0.37, 5.83) (2; 86.0%)	9.68 (4.53, 20.7) (2; 45.3%) *	3.07 (0.74, 12.8) (2; 95.5%)	5.27 (2.78, 9.98) (5; 76.4%) *
Retrospective cohort	2.96 (1.93, 4.54) (12; 99.8%) *	2.77 (1.90, 4.06) (4; 45.9%) *	1.99 (1.01, 4.48) (2; 96.3%) *	4.72 (3.09, 7.19) (8; 99.6%) *
Type of stroke
Ischaemic	2.89 (1.77, 4.72) (13; 99.6%) *	4.26 (2.44, 7.44) (7; 89.9%%) *	2.44 (1.33, 4.48) (4; 94.2%) *	5.14 (4.08, 6.49) (13; 77.0%) *
Sample size
≥500	2.57 (1.65, 4.00) (10; 99.9%) *	4.36 (2.11, 9.01) (4; 94.7%) *	2.86 (1.34, 6.13) (3; 95.7%) *	5.57 (3.79, 8.19) (9; 99.5%) *
<500	3.38 (1.05, 10.9) (5; 86.1%) *	4.07 (2.18, 7.6) (3; 0.0%) *	1.49 (1.01, 2.20) (1; ---) *	3.54 (1.55, 8.12) (5; 78.2%) *
Location
Asia	2.66 (1.56, 4.55) (94%)*	-	-	4.16 (2.22, 7.64) (89.9%)*
Europe	2.44 (1.33, 4.48) (88%)*			4.46 (1.21, 16.39) (77%)*
North America	3.29 (1.37, 7.91) (99%)*			4.46 (2.65, 7.56) (99%)
Others	12.21 (4.08, 36.51) (99%)

*indicates statistical significance at p<0.05.